Pfizer Corporation

Warner-lambert Company

Pfizer Products Inc.

Douglas Scott Johnson

Patrick Robert Verhoest

Martin Youngjin Pettersson

Christopher William Am Ende

Cory Michael Stiff

Chakrapani Subramanyam

Christopher John O'Donnell

Michael Eric Green

Tuan Phong Tran

Antonia Friederike Stepan

Gregory Wayne Kauffman

Michael Aaron Brodney

Bruce Nelsen Rogers

Adam Matthew Gilbert

Christopher Ryan Butler

Christopher John Helal

Steven Victor O'Neil

Elizabeth Mary Beck

Justin Ian Montgomery

Nandini Chaturbhai Patel

Laura Ann McAllister

Damien Webb

Christopher John O'donnell

Joseph Thomas Repine

Andrew David White

Benjamin Adam Fish

Patrick Bradley Mullins

Thayalan Navaratnam

William Alexander Denny

Scott E Lazerwith

Lijuan Jane Wang

Gordon William Rewcastle

James S Kaltenbronn

Daniele Marie Leonard

Suzanne Ross Kesten

Ho Huat Lee

Marvin Jay Meyers

John Michael Humphrey

Jared Bruce John Milbank

Richard H Hutchings

Mark Anthony Morris

Danica Antonia Rankic

Lorraine Kathleen Fay

Scott Edward Lazerwith

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R, R, R, R, R, R, R, R, R, R, R, and y are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Cyclopropabenzofuranyl pyridopyrazinediones

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Bicyclic pyridinones

The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.

Biaryl ether urea compounds

This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R, and Rthrough Rare defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

The present invention provides novel 5-substituted tetralones of Formulas I, II, III, and IV and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme

5-substituted tetralones as inhibitors of ras farnesyl transferase

Growing community of inventors

Concord, MA, United States of America

Douglas Scott Johnson